. 2023 May 21;15(10):2855. doi: 10.3390/cancers15102855

Table 2.

Current clinical trials for each drug class.

Drug Class	Clinical Trials	Description
ICI	Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1) [127]	Assessing for a therapeutic advantage to administering ICI and VEGEF inhibitor to patients previously receiving immunotherapy.
EGFR Inhibitors	An Open-label, Single-Arm, Phase II Trial of Stereotactic Body Radiotherapy for Patients With Residual Oligometastases of NSCLC After 3rd Generation EGFR-TKIs [128]	After administering 3rd generation EGFR-TKIs, SBRT will be given until regression or intolerance.
ALK Inhibitors	Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor [129]	Identifying alterations in the ALK gene that may confer benefit from ALK inhibitor therapy.
MET Inhibitors	Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer [130]	Local or metastatic NSCLC patients with a METex14 mutation, not undergoing chemotherapy.
RET Inhibitors	A Phase I Study of Oral LOXO-260 in Patients With RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and other Tumors with RET Activation Refractory to Selective RET Inhibitors [131]	Testing of a next-generation RET inhibitor, which has exhibited in vitro effect against RET-positive tumors with acquired resistance mutations.
Bispecific Antibodies	AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC [132] AK104 Monotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer [133]	Investigating the effect of an anti-PD1 and VEGF bispecific antibody in combination with platin and paclitaxel chemotherapy. AK104 is a tetravalent bispecific antibody targeting PD-1 and CTLA-4; this study aims to evaluate its efficacy and safety profile.
CAR T Cells	Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC [134]	Early Phase I study investigating the pharmacokinetics and anti-tumor effect of a novel CAR T cell.